Gene Molecular Alterations as Disease Prognostic Markers in Patients With Non-small Cell Lung Cancer (NSCLC)

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 367

Sponsor: Hellenic Cooperative Oncology Group

Summary

GEMA-proN is an observational, multicenter, single cohort, retrospective clinical trial. The aim of the trial is to assess the prevalence, and prognostic value of genetic molecular alterations and investigate correlations with clinicopathological features in unselected patients with histologically confirmed non-small cell lung cancer (NSCLC).

Eligibility Criteria

Inclusion Criteria: * Age 18 and above. * Histologically confirmed non-small cell lung cancer (NSCLC). * Adequate, and suitable tissue for the testing of somatic genetic alterations. Exclusion Criteria: \- Patients with personal medical history of malignancy, other than non-small cell lung cancer (NSCLC), with the exclusion of completely resected non-melanoma skin cancers, in situ carcinomas of the cervix uteri, in situ bladder carcinomas, in situ ductal breast carcinoma, and other cancers treated with curative intent with no evidence of disease recurrence for 5 years.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06876402). StuddyBuddy aggregates publicly available trial information.